What is Replimune Group's remainder of fiscal year 2024?

Replimune Group (REPL) reported remainder of fiscal year 2024 of $302K in Q4 2025.

How has Replimune Group's remainder of fiscal year 2024 changed year-over-year?

Replimune Group's remainder of fiscal year 2024 increased by 4.5% year-over-year, from $289K to $302K.

Replimune Group REPL Remainder of Fiscal Year 2024

Remainder of Fiscal Year 2024 at other companies

AmgenAMGN

——

Inhibrx Biosciences, Inc.INBX

——

ImmunityBio, Inc.IBRX

——

ModernaMRNA

——

Other financials

Income statement

See full

Operating income-$71.9M-8.9%

Net income-$70.9M-6.9%

EPS (diluted)-$0.77+2.5%

Balance sheet

See full

Cash & equivalents$124.7M-28.3%

Total debt$79.2M+0.5%

Total equity$210.5M-56.4%

Total assets$333.6M-44.7%

Cash flow

See full

Operating cash flow-$66.0M-30.1%

CapEx$135.0K-92.5%

Free cash flow-$66.1M-25.9%

Valuation

See full

Market cap$930.59M+28.6%

Enterprise value$885.15M+28.3%

Returns & leverage

See full

Return on equity-90.9%+362pp

Debt / equity0.4×+0.2×

Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's remainder of fiscal year 2024.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Replimune Group's remainder of fiscal year 2024?: Replimune Group (REPL) reported remainder of fiscal year 2024 of $302K in Q4 2025.
How has Replimune Group's remainder of fiscal year 2024 changed year-over-year?: Replimune Group's remainder of fiscal year 2024 increased by 4.5% year-over-year, from $289K to $302K.